PerkinElmer
check quantity

Genhance 680 Fluorescent Imaging Agent (1mg)

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV10117
180.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Genhance™ 680 is the acid form of VivoTag® 680 that can be used as a control or a fluorescent in vivo blood pool imaging agent. Upon dilution, a 1 mg package of Genhance 680 fluorescent imaging agent provides sufficient reagents for imaging approximately 20 mice (weighing ~25 grams each) when using the recommended dose of 0.05mg/100 µL 1xPBS.

The generally recommended procedure for in vivo imaging with Genhance 680 is administration via tail vein injection and imaging 30 minutes post injection. 

Specifications

Fluorescent Agent Type Vascular
Optical Imaging Classification Fluorescence Imaging
Product Brand Name Genhance
Shipping Condition Ambient
Unit Size 1 mg
Wave Length 680 nm
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Technical Note

Genhance 680 (1 mg) (Data Sheet)

Genhance™ 680 is the acid form of VivoTag® 680 that can be used as a control or a fluorescent in vivo blood pool imaging agent.,Upon dilution, a 1mg package of Genhance 680 provides sufficient reagents for imaging approximately 20 mice (weighing ~25 grams each) when using the recommended dose of 0.05mg/100 µL 1xPBS.

PDF 54 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB